Issue 2 - The Cancer Letter

Vol.

No.

January 15, 2021Jan 15, 2021

DOWNLOAD THE PDF

Cover Story

Gordon Zubrod's panoramic vision shaped modern clinical cancer research
The Cancer History Project finds and publishes Zubrod's autobiography

By Otis W. Brawley and Paul Goldberg

In histories of oncology, Charles Gordon Zubrod is a name that flashes by quickly, someone who did something important a long time ago.

Conversation with The Cancer Letter

Sean Khozin named CEO of CancerLinQ: AI is here, and it will become even more democratized

By Matthew Bin Han Ong

Improvements in treatments for NSCLC, blood cancers, and melanoma continue to accelerate annual drop in overall cancer mortality rates

By Alexandria Carolan and Matthew Bin Han Ong

FDA to update labels for generic cancer drugs with signing of MODERN Labeling Act

By Matthew Bin Han Ong

Clinical Trials & Tribulations

An oncologist's perspective on measuring success in the clinic

By Steven R. Grossman

In Brief

Charles S. Fuchs named SVP at Roche and Genentech

Crystal Denlinger named chief scientific officer of NCCN

Jonathan Weinbach named CEO of New York Proton Center

Christian Hinrichs named chief of immunology program at Rutgers

Kenneth H. Kim to direct Cedars-Sinai Women's Cancer Program

Sonali M. Smith named chief of the Hematology/Oncology at University of Chicago

Tisch Cancer Institute receives $1.9 million NCI grant for cancer metastasis research

Fox Chase receives grant to research radiation in metastatic colorectal cancer

MSK launches podcast: “Cancer Straight Talk from MSK”

Clinical Roundup

IU cancer center findings could reduce treatment-related complication for blood cancer patients

Study: Young people using e-cigarettes are three times more likely to become daily cigarette smokers

Drugs & Targets

Xalkori receives FDA approval for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma

Pvsripo receives Orphan Drug Designation from FDA for advanced melanoma treatment

Illumina collaborates with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to advance comprehensive genomic profiling

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Sean Khozin named CEO of CancerLinQ: AI is here, and it will become even more democratized

Improvements in treatments for NSCLC, blood cancers, and melanoma continue to accelerate annual drop in overall cancer mortality rates

FDA to update labels for generic cancer drugs with signing of MODERN Labeling Act

An oncologist's perspective on measuring success in the clinic

In Brief

Charles S. Fuchs named SVP at Roche and Genentech

Crystal Denlinger named chief scientific officer of NCCN

Jonathan Weinbach named CEO of New York Proton Center

Christian Hinrichs named chief of immunology program at Rutgers

Kenneth H. Kim to direct Cedars-Sinai Women's Cancer Program

Sonali M. Smith named chief of the Hematology/Oncology at University of Chicago

Tisch Cancer Institute receives $1.9 million NCI grant for cancer metastasis research

Fox Chase receives grant to research radiation in metastatic colorectal cancer

MSK launches podcast: “Cancer Straight Talk from MSK”

Clinical Roundup

IU cancer center findings could reduce treatment-related complication for blood cancer patients

Study: Young people using e-cigarettes are three times more likely to become daily cigarette smokers

Drugs & Targets

Xalkori receives FDA approval for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma

Pvsripo receives Orphan Drug Designation from FDA for advanced melanoma treatment

Illumina collaborates with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to advance comprehensive genomic profiling

Recent Issues

Trending Stories

Renew today!

Subscriber content

Login